|Chemical and physical data|
|Molar mass||340.523 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT7 receptor partial inverse agonist, and was the first such ligand identified for 5-HT7. Its use in research has mainly been in demonstrating the potential use for 5-HT7 agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT7 agonists across several different testing models.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|